Investment Thesis
HeartFlow demonstrates strong fundamentals in revenue growth (39.9% YoY) and exceptional gross margins (76.8%), indicating solid product-market fit in the medical device sector. However, severe operating losses (-$36.4% margin), significant cash burn (-$59M FCF), and less than one year of cash runway present material execution risk and likely require near-term profitability progress or capital raise.
Strengths
- Strong revenue growth of 39.9% YoY ($176M) demonstrates robust market demand and adoption
- Exceptional gross margin of 76.8% indicates strong product economics, pricing power, and operational efficiency
- Fortress balance sheet with zero debt, $300.6M stockholders equity, $44.8M cash, and excellent liquidity (5.20x current ratio)
Risks
- Critical cash burn of -$59M annually (FCF margin -33.5%) with approximately 9 months of runway at current burn rate
- Severe unprofitability with -$116.8M net loss and -$36.4% operating margin despite strong gross margins, indicating unsustainable OpEx structure
- Must achieve profitability or raise capital soon; dilution risk or forced cost restructuring could impair shareholder value
Key Metrics to Watch
- Operating expense ratio trend relative to revenue growth and path to operating profitability
- Free cash flow inflection point and monthly cash burn rate
- Gross margin sustainability and revenue growth deceleration at scale
Financial Metrics
Revenue
176.0M
Net Income
-116.8M
EPS (Diluted)
$-3.17
Free Cash Flow
-59.0M
Total Assets
359.5M
Cash
44.8M
Profitability Ratios
Gross Margin
76.8%
Operating Margin
-36.4%
Net Margin
-66.3%
ROE
-38.8%
ROA
-32.5%
FCF Margin
-33.5%
Balance Sheet & Liquidity
Current Ratio
5.20x
Quick Ratio
5.20x
Debt/Equity
0.00x
Debt/Assets
16.4%
Interest Coverage
N/A
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-04-11T09:48:28.192533 |
Data as of: 2025-12-31 |
Powered by Claude AI